Loading stock data…
Vaxcyte (PCVX)
$60.36-0.80 (-1.31%)
Market ClosedLast close Sep 8
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vaxcyte, Inc. in the Healthcare sector is trading at $60.36 with a market capitalization of $7.1B. Wall Street consensus targets $109.00 (9 analysts), implying a +80.6% move over the next 12 months. The stock is currently near its 52-week high of $65.00, remaining 11.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +80.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$345.85M↓ | -$274.28M↓ | -$242.38M↓ | -$226.22M↓ | -$180.79M |
| Net Income | -$320.62M↓ | -$246.51M↓ | -$212.83M↓ | -$166.57M↓ | -$140.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.59%
Volume
Today's trading volume
1.02M
Recent News
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million.
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions.
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings.
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due […]
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how you should read every 13F going forward.